GSK Begins Shipping Doses Of Quadrivalent Influenza Vaccines To US For 2023-24 Flu Season

Nuvalent Stock Climbs 39% On $10.6 Bln Takeover Deal With GSK

Shares of Nuvalent, Inc. were surging around 39 percent in the pre-market activity on the Nasdaq, after the clinical-stage biopharma company focused on cancer therapies agreed to be acquired by British drug major GSK plc, in a deal valued at $10.6 billion or 8.0 billion pounds. Further, GSK maintained its 2026 guidance range of 7 percent to 9 percent growth in core operating profit and core EPS.

RTTNews | 94 days ago

GSK Stock Up On Q4 Results, Positive Outlook; Plans To Buyback GBP 2 Bln Shares

Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, after the British drug maker reported Wednesday a higher fourth-quarter results and issued positive outlook for fiscal 2025. The company further raised its sales view for fiscal 2031, and announced dividends and 2 billion pounds share buyback programme.

RTTNews | 583 days ago

GSK Q3 Results Down, Sees FY24 Outlook At Mid Range; Stock Drops

Shares of GSK plc were losing more than 4 percent on the London Stock Exchange as well as in the early morning trading on the NYSE after the British drug maker reported Wednesday sharply lower profit in its third quarter on $2.3 billion charge on Zantac settlement, as well as weak revenues. Further, GSK confirmed its fiscal 2024 outlook for earnings, core profit and sales.

RTTNews | 681 days ago

GSK Reaches Confidential Settlement With Ronald Kimbrow Involving Ranitidine

GSK plc (GSK, GSK.L) announced Monday it has reached a confidential settlement with Ronald Kimbrow resolving the case he filed in Illinois state court. GSK does not admit any liability in this settlement. The case will now be dismissed as to GSK.

RTTNews | 774 days ago

GSK Inks License Deal With China's Hansoh Pharma For HS-20093; To Pay Up To $1.7 Bln

GSK plc (GSK, GSK.L) and Chinese biopharmaceutical company Hansoh Pharma announced Wednesday that they have entered into an exclusive license agreement for HS-20093, a B7-H3 targeted antibody-drug conjugate (ADC) utilizing a clinically validated topoisomerase inhibitor (TOPOi) payload.

RTTNews | 996 days ago

GSK Lifts FY23 Outlook As Q3 Profit From Cont. Opns Surges

British drug major GSK Plc on Wednesday lifted its fiscal 2023 forecast for earnings and sales after reporting higher third-quarter profit on continuing operations basis. The results were benefited by vaccines' performance, mainly the US launch of Arexvy, the world's first RSV vaccine. Total profit for the quarter, meanwhile, plunged from last year on the absence of prior year's hefty gain.

RTTNews | 1045 days ago

IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).

RTTNews | 1117 days ago

GSK, SCYNEXIS Ink Exclusive Licence Agreement For Brexafemme

GSK plc (GSK, GSK.L) and SCYNEXIS, Inc. (SCYX) announced Thursday they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC (RVVC).

RTTNews | 1261 days ago

EURUSD	1.16033	GBPUSD	1.35195
USDJPY	153.538	USDCAD	1.3861